Skip to Content
MilliporeSigma
All Photos(1)

Documents

SML3054

Sigma-Aldrich

CHIR124

≥98% (HPLC)

Synonym(s):

4-[((3S)-1-Azabicyclo[2.2.2]oct-3-yl)amino]-3-(1H-benzimidazol-2-yl)-6-chloroquinolin-2(1H)-one, 4-[(3S)-1-Azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)-6-chloro-2(1H)-quinolinone, CHIR 124, CHIR-124, f 4-[((3S)-
quinuclidin-3-yl)amino]-3-benzimidazol-2-yl-6-chloro-hydroquinolin-2- one

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C23H22ClN5O
CAS Number:
Molecular Weight:
419.91
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C1NC2=CC=C(Cl)C=C2C(N[C@@H]3CN4CCC3CC4)=C1C5=NC6=C(C=CC=C6)N5

InChI

1S/C23H22ClN5O/c24-14-5-6-16-15(11-14)21(25-19-12-29-9-7-13(19)8-10-29)20(23(30)28-16)22-26-17-3-1-2-4-18(17)27-22/h1-6,11,13,19H,7-10,12H2,(H,26,27)(H2,25,28,30)/t19-/m1/s1

InChI key

MOVBBVMDHIRCTG-LJQANCHMSA-N

Biochem/physiol Actions

CHIR124 is a potent and selective inhibitor of checkpoint kinase 1 (Chk1)( IC50 = 0.3 nM) that produces G2-M abrogation which induces chemosensitisation. It also inhibits PDGFR and FLT3 (IC50 = 6.6 nM and 5.8 nM respectively). CHIR-124 inhibits Pgp activity in multidrug-resistant cell lines KB-V1 and A2780-Pac-Res.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rida Zahra et al.
PloS one, 15(6), e0233993-e0233993 (2020-06-03)
Multidrug resistance (MDR) to chemotherapeutic drugs remains one of the major impediments to the treatment of cancer. Discovery and development of drugs that can prevent and reverse the acquisition of multidrug resistance constitute a foremost challenge in cancer therapeutics. In
Archie N Tse et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 13(2 Pt 1), 591-602 (2007-01-27)
Chk1 kinase is a critical regulator of both S and G(2)-M phase cell cycle checkpoints in response to DNA damage. This study aimed to evaluate the biochemical, cellular, and antitumor effects of a novel Chk1 inhibitor, CHIR124. CHIR-124 was evaluated
Siang-Boon Koh et al.
Cancer research, 78(11), 3054-3066 (2018-05-08)
Combination of cytotoxic therapy with emerging DNA damage response inhibitors (DDRi) has been limited by tolerability issues. However, the goal of most combination trials has been to administer DDRi with standard-of-care doses of chemotherapy. We hypothesized that mechanism-guided treatment scheduling

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service